HIJ-PROPER trial -- Intensive cholesterol-lowering treatment: No significantly better outcomes

(European Society of Cardiology) Survival and other cardiovascular outcomes were not significantly reduced with intensive treatment using a second-line cholesterol-lowering medication on top of a standard statin, compared to statin treatment alone in patients with acute coronary syndrome and dyslipidemia, investigators reported here.